Xenon Pharmaceuticals Inc.
XENE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001582313
In the last 90 days, Xenon Pharmaceuticals Inc. insiders filed 2 open-market purchases and 1 sale; 285 institutions reported holding it in 13F filings for Q3 2026, worth $3.76B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 18, 2026
- $3.71B
- Insider buysLast 90 days, $1.68M in total
- 2
- Insider sellsLast 90 days, $425.8K in total
- 1
- 13F holdersQ3 2026, −25 vs. previous quarter
- 285
- 13F valueReported value at the end of Q3 2026
- $3.76B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $7.50M
- No comparable prior period
- Net income, FY2025
- -$345.9M
- No comparable prior period
- Free cash flow, FY2025
- -$279.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $345.9M (4612.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 7.36M
- Shares sold short
- Change
- +14.8K
- +0.2% vs. previous
- Days to cover
- 6.36
- At average daily volume
Superinvestors holding XENE, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding XENE at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Xenon Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 (view filing)9:20 AM ET | Sep 30 | 1 day | Kelly Thomas PatrickChief Financial Officer | PPurchase | +15.0K | $37.32 | +$559.7K | New position15.0K after | |
| Oct 1, 2026 (view filing)9:19 AM ET | Sep 30 | 1 day | Mortimer IanPRESIDENT & CEO | PPurchase | +30.0K | $37.38 | +$1.12M | +150.6%49.9K after | |
| Aug 31, 2026 (view filing)9:59 PM ET | Aug 28 | 3 days | Kenney Christopher JohnChief Medical Officer | SSale | −7.07K | $60.25 | −$425.8K | −100.0%2 after | 2 lots10b5-1 |
| Aug 13, 2026 (view filing)4:33 PM ET | Aug 11 | 2 days | Gannon StevenDirector | SSale | −10.0K | $64.06 | −$640.5K | −84.2%1.87K after | |
| Jun 8, 2026 (view filing) | Jun 5 | 3 days | Patou GaryDirector | SSale | −1.32K | $53.14 | −$70.3K | −5.0%24.9K after | 10b5-1 |
| Jun 8, 2026 (view filing) | Jun 5 | 3 days | Cannon GillianDirector | SSale | −1.19K | $53.14 | −$63.2K | −45.0%1.46K after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 13 | Same day | Kenney Christopher JohnChief Medical Officer | SSale | −1.41K | $55.23 | −$77.9K | −16.6%7.07K after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 13 | Same day | DiFabio AndreaChief Legal Officer | SSale | −1.34K | $55.23 | −$74.1K | −15.5%7.30K after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 13 | Same day | Mortimer IanPRESIDENT & CEO | SSale | −7.31K | $55.23 | −$403.6K | −26.8%19.9K after | 10b5-1 |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Kenney Christopher JohnChief Medical Officer | SSale | −2.77K | $60.11 | −$166.6K | −36.9%4.73K after | 10b5-1 |
Top 10 13F holders, Q3 2026
See all 285 holdersThe largest institutional positions in Xenon Pharmaceuticals Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 11,554,454 | $429.7M | 0.02% | +1,906,456+19.8% | Added |
| T. Rowe Price Investment Management, Inc. | 7,896,803 | $293.7M | 0.21% | +5,728,222+264.1% | Added |
| BlackRock, Inc. | 7,710,413 | $286.8M | 0.00% | +187,931+2.5% | Added |
| Avoro Capital Advisors LLC | 5,500,000 | $204.5M | 2.11% | −277,777−4.8% | Reduced |
| Polar Capital Holdings Plc | 5,022,084 | $186.8M | 0.52% | +451,528+9.9% | Added |
| Janus Henderson Group PLC | 4,002,869 | $148.8M | 0.06% | +4,002,869 | New |
| Driehaus Capital Management LLC | 3,557,546 | $132.3M | 0.92% | −861,011−19.5% | Reduced |
| Price T Rowe Associates Inc | 3,178,798 | $118.2M | 0.01% | −69,421−2.1% | Reduced |
| Capital International Investors | 2,359,559 | $87.8M | 0.02% | −2,080−0.1% | Reduced |
| State Street Corp | 2,057,284 | $76.5M | 0.00% | +87,655+4.5% | Added |
Holders of 5% or more of XENE
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Xenon Pharmaceuticals Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 11.50%11.1M shares | +1.20 ppfrom 10.30% | Feb 8, 202110 filings | Nov 5, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G/A | 10.30%10.0M shares | +2.10 ppfrom 8.20% | Nov 6, 20262 filings | Nov 6, 2026 | SEC |
| Avoro Capital Advisors LLC | 13G/A | 6.26%5.78M shares | – | Feb 12, 20215 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.20%4.76M shares | New | Jul 17, 20251 filing | Jul 17, 2025 | SEC |
| Polar Capital Holdings Plc | 13G | 5.19%5.02M shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |